Mereo BioPharma and Sentynl Therapeutics sign licensing deal for alvelestat

PartnershipalvelestatPositive

AI Analysis

Summary

Mereo BioPharma and Sentynl Therapeutics signed an option and licence agreement granting Mereo the US commercial and worldwide manufacturing rights to alvelestat, an oral treatment candidate for AATD-LD.

Importance:6/10

Sentiment:

0.30

licensingpartnershipcommercializationmanufacturing rights

Related Companies

$OPTN

Read the original article

Published by Pharmaceutical Technology on August 12, 2026 9:14 AM

Read Original